Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Bayer’s Stivarga First Drug To Enter Brain Cancer Platform Trial

Fri, 06/21/2019 - 6:04am

GBM AGILE is the first global adaptive clinical trial platform for glioblastoma and the German group's liver and colorectal cancer...

      Related Stories 

Lupin Boss On Getting Biosimilar Manufacturing Right, Albuterol Outlook

Thu, 06/20/2019 - 6:15pm

Lupin managing director tells Scrip that manufacturing competence will be a “big advantage” in the biosimilars space, and also believes...

      Related Stories 

Genexine Hopes To Become 'Asia’s Amgen' After ToolGen Merger

Thu, 06/20/2019 - 5:08pm

With an ambition to become an Amgen-like global biopharma, South Korea's Genexine decides to merge with local genome editing firm...

      Related Stories 

Ready To Ride Next Growth Wave In China? Remember Five Keys

Thu, 06/20/2019 - 3:50pm

As China enters a new growth spur for the health sector, underscored by faster product approvals, annual reimbursement coverage and...

      Related Stories 

Keytruda Rules The Roost, But Merck & Co. Highlights Progress In Other Areas

Thu, 06/20/2019 - 12:39pm

Merck & Co. outlined its near-term growth drivers during an investor day, including Keytruda in breast and prostate cancer, as...

      Related Stories 

Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager

Thu, 06/20/2019 - 10:51am

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with...

      Related Stories 

Deal Watch: Sanofi Continues To Opt Out Of CNS Tie-Up With Voyager

Thu, 06/20/2019 - 10:51am

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with...

      Related Stories 

UCB Buoyed By More Positive Bimekizumab Data

Thu, 06/20/2019 - 5:19am

The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is...

      Related Stories 

AML Contender Quizartinib Gains First Approval, In Japan

Wed, 06/19/2019 - 9:27pm

Japan grants first approval worldwide for Daiichi Sankyo's oral FLT3 inhibitor, marking progress for Japanese firm's global oncology ambitions.

      Related Stories 

Sanofi’s Ameet Nathwani Brings Life Sciences R&D Expertise To The Digital Space

Wed, 06/19/2019 - 1:12pm

Nathwani talks to Scrip about his unique dual role as chief medical officer and chief digital officer, Sanofi’s approach to...

      Related Stories 

No-Deal Brexit 'Very Bad' For Business And Patients

Wed, 06/19/2019 - 11:25am

Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns...

      Related Stories 

Japanese OK In COPD Gives AstraZeneca’s Breztri Aerosphere First Regulatory Approval

Wed, 06/19/2019 - 9:08am

AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and...

      Related Stories 

Tremfya And Taltz Provide PsA Highlights At EULAR

Wed, 06/19/2019 - 3:35am

The spotlight was on anti-interleukin drugs at the Madrid meeting last week, especially their role in advancing the treatment of...

      Related Stories 

AstraZeneca Plans $630m Korea Investment Amid Favorable Policies

Tue, 06/18/2019 - 11:06pm

AstraZeneca plan hefty investment in South Korea’s biomedical sector over next few years, signaling multinationals' improved sentiment over the government’s...

      Related Stories 

Pages